It looks like the stock has bottomed. I don't think it
will go much lower than 15 before the results are reported.
As a reminder, here is an excerpt from the Texas WSJ, April 9 (from post #169):
`Those willing to shoulder some risk should buy now,
analysts say. Urologists involved in Vasomax's current
late-stage Phase III U.S. trials say the drug appears to be
effective. When Zonagen takes the wraps off a six-month
study of some 900 U.S. men, "I think it will show positive
and statistically significant results," says Harin
Padma-Nathan, an associate professor of urology at the
University of Southern California and director of the Male
Clinic in Santa Monica, Calif., one of the larger centers
participating in the clinical trials.
`In Phase III trials, researchers seek to determine the
effectiveness of a drug compared with a placebo in human
patients. Dr. Padma-Nathan says many of his patients who
have elected to go into the "open-label" stage of the study --
in which they are no longer given placebos but the drug itself
-- "have been very happy with the results."
`Likewise, Irwin Goldstein, a professor of urology at Boston
University who also has patients enrolled in Zonagen's
study, says his research on human penile tissue "clearly
shows that Vasomax has actions to enhance erections." He
estimates that Vasomax, because it appears to be safe and
effective, has the potential "to be a billion-dollar drug."
Last year, in a Phase III trial of about 150 men in Mexico --
a prototype for the U.S. study -- Zonagen found that 42%
of patients with varying degrees of impotence were able to
achieve an erection and maintain it until orgasm every time
they took the pill. Joseph Podolski, Zonagen's president and
CEO, says, "we expect we will see similar results" in the
U.S.' |
